Cognitive function, often impaired in conditions with raised ICP such as IIH, was not adversely affected by exenatide treatment in an exploratory study of women with IIH over 12 weeks [100]
Another provider prescribed 20 units instead of 2, affecting three patients who, after receiving 10 times the intended dose, experienced nausea and vomiting
The CagriSema trials used 2.4 mg as the target, and the Phase 3 monotherapy data also used 2.4 mg
Once the mechanism works, the question shifts from who can build it to who controls it, and that's where most teams are underprepared." Across the landscape: Novo Nordisk is building across multiple triple-agonist assets Pfizer has entered through acquisition Hanmi is advancing the only clinical-stage small-molecule triple Innovent, Hengrui, and multiple Chinese sponsors are scaling pipeline depth Sanofi holds the largest IP position without a disclosed asset 27 programs
The maximum retatrutide dose currently being studied in major Phase 3 obesity trials is 12mg once weekly